FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
gilteritinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
gilteritinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New B)
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
midostaurin Sensitive: A2 - Guideline
|
midostaurin Sensitive: A2 - Guideline
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline
|
cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
venetoclax + azacitidine Sensitive: B - Late Trials
|
venetoclax + azacitidine Sensitive: B - Late Trials
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
LY3009120 Sensitive: C3 – Early Trials
|
LY3009120 Sensitive: C3 – Early Trials
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
venetoclax + gilteritinib Sensitive: C3 – Early Trials
|
venetoclax + gilteritinib Sensitive: C3 – Early Trials
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
sorafenib + gilteritinib Sensitive: C3 – Early Trials
|
sorafenib + gilteritinib Sensitive: C3 – Early Trials
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
JRF104 Sensitive: D – Preclinical
|
JRF104 Sensitive: D – Preclinical
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
PHI-101 Sensitive: D – Preclinical
|
PHI-101 Sensitive: D – Preclinical
|